Chronic PainEarly Phase 1NCT00677911
Immunologic Response to Negative Cognition in Persons With Chronic Pain
A Early Phase 1 study testing In-vivo pain catastrophizing induction in people with Chronic Pain, run by Oregon Health and Science University at 1 site in United States.
Trial summary
Principal Investigator/Program Director (Last, First, Middle): Darnall, Beth APS Future Leaders in Pain Small Research Grants Application Page 5 Continuation Format Page Summary: Chronic pain is stressful, both physically and psychologically. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Chronic Pain
- What is being tested?
- In-vivo pain catastrophizing induction
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 47 participants
- Where
- 1 siteUnited States
- Study dates
- Feb 2007to Dec 2007
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ages 18-65
- chronic musculoskeletal pain
- being treated for chronic pain at OHSU
Who cannot join
- suicidality or thought disorder
- pregnant
- poor venous access
- current corticosterioid regimen
- recent or active virus or infection
- substance abuse
- former IV drug user
Trial locations and contacts
1 site in 1 country.
United States1 site
OCTRI; OHSU Mail Code: CHH 13th floor 3303 Bond St.
Portland, Oregon, 97239
About this study
Principal Investigator/Program Director (Last, First, Middle): Darnall, Beth APS Future Leaders in Pain Small Research Grants Application Page 5 Continuation Format Page
Summary: Chronic pain is stressful, both physically and psychologically. Stressful experiences induce autonomic nervous system arousal, which reliably leads to inflammation and immune suppression. Inflammation then exacerbates existing pain and may be a key factor in both the genesis and maintenance of pain. Stress-induced immune effects are detected two hours (2 hrs) post-stressor, suggesting only a few stressful experiences per day may be sufficient to sustain elevated pain levels1. Cognition has emerged as a potential mediating factor in the relationship between pain and stress. Mentally recreating an emotionally stressful event induces de novo physiological stress1. In other words, thinking about an emotionally charged event down-regulates autonomic stress responses and subsequent immune effects. Therefore, exploring cognition as a mediating factor between stress, pain, and inflammation will inform our understanding of pain pathways, as well as improve treatment for pain.
Read more
Study Rationale: The acute stress response induces immunosuppression; however, this relationship has been studied in arbitrary models only (shock avoidance, job interview). This study employs the novel approach of examining stress and immune responses to a personally relevant stressor (pain); prior studies used arbitrary models only (shock avoidance, job interview). Pain offers a highly salient and personal context well-suited for investigation of negative cognitive perseveration. Pain is acutely sensitive to exacerbation via inflammation, and thus the relevance of examining immune effects of rumination on future negative expectations ("expecting the worst") is underscored.
Goal: To test the biological consequences of negative expectations, achieved via an active 10-minute negative cognitive perseveration on a personally relevant stressor: future worsening of one's chronic pain condition. Biological stress response will be measured via heart rate (HR), blood pressure (BP) and serum cortisol. Impact of negative cognition on inflammation will be measured using interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) as biomarkers of immune function, controlling for depression and pain catastrophizing. This study aims to inform the understanding of pain mechanisms.
Aim 1: Determine the magnitude of an autonomic stress response to an induction of negative cognition.
Aim 2: Determine immune effects of the experiment-induced stress response.
Aim 3: Establish whether a pre-existing tendency to catastrophize mediates the relationship between experiment-induced negative perseveration and immune effects.
Aim 4: Establish whether stress-related increases in IL-6 remain elevated post 2 hrs.
Read the detailed description
Methods: This prospective study examines the magnitude of biological stress and subsequent immunologic changes in response to negative cognitive perseveration. Five physiological measurement time points occur over the course of the 3 hour experiment.
Demographics and health characteristics of interest: gender, marital status, smoking status, education level, race, height, weight, body mass index, medical comorbidity, psychological comorbidity, medications (for inflammation, pain, or psychiatric conditions).
Inclusionary Criteria
- >18 years of age; <65 years of age
- Non-inflammatory musculoskeletal patients presenting for evaluation at Oregon Health \& Science University (OHSU) Comprehensive Pain Center (CPC)
Exclusionary Criteria
- Active or recent virus/infection
- Thought disorder, Suicidality,
- Substance Abuse
- Active corticosteroid regimen
- Pregnancy
- Limited venous access
- Former intravenous drug user
Enrollment: All persons presenting for evaluation at the CPC who meet study criteria will be offered the option to participate in the study. Approximately 60 new pain patients are evaluated by psychology monthly and we expect to obtain our goal of 40 participants within 6 months. Informed consent will be obtained in compliance with OHSU Institutional Review Board protocol. Subjects will receive $100 gift certificate compensation, even if they fail to complete the study. We anticipate a low completion failure rate as the study is completed in one 3-hour time block. Study times will be standardized to account for circadian effects. Participants will be told to arrive having eaten a light breakfast with minimal caffeine consumption (e.g., less than 2 cups of coffee). They will be given a subject number and their psychiatric diagnoses will be blinded to prevent bias. The study involves gathering 5 serum samples and thus participants will be catheterized by nursing staff to minimize physiological stress.
Principal Investigator/Program Director (Last, First, Middle): Darnall, Beth APS Future Leaders in Pain Small Research Grants Application Page 7 Continuation Format Page
Study site: The study will be conducted at the NIH-funded General Clinical Research Center (GCRC). The GCRC provides state of the art resources including research space, specialized research nurses to perform blood draws and gather biodata, biostatisticians, and sophisticated laboratories to perform serum biomarker analysis. OHSU's GCRC is Oregon's premier multidisciplinary patient-oriented research facility and is housed in the same building as the CPC, thus minimizing travel burden on participants.
Active Stress Induction: Negative Cognitive Perseveration On their experiment day, participants will interface with a licensed clinical psychologist who did not perform their clinical interview and who is blinded to their diagnoses. The psychologist will instruct the participant talk for 10 minutes about the worst aspects of their pain, to discuss their loss of control over their situation, the negative impact pain has had on their life and others. They will be guided to imagine that their situation will progressively worsen, and to focus on how badly they will feel as a result. Two measures of induction efficacy will be given: subjective verbal rating (0-10) and objective rating by attending psychologist (0-10). The intervention ends at 10 minutes and the remainder of the study involves biodata measurement.
Study ends at 2.5 hrs post induction following the final blood draw. The psychologist will debrief subjects and will assess their affective state. Their subjective units of distress will be checked. Persons who are in a continued negative cognitive state will receive 30 minutes of Cognitive Behavioral Therapy (CBT) by the on-site psychologist. Care will be taken not to allow participants to leave the study site in distress. Participants will receive follow up psychology care at the CPC as indicated in their treatment plan.
- Conditions
- Chronic Pain
- Being tested
- In-vivo pain catastrophizing induction
- Keywords
- Chronic pain, Interleukin-6, pain catastrophizing, cytokines, cortisol
- Medical subject headings
- Chronic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
In-vivo pain catastrophizing inductionBehavioural
All participants underwent a 10-minute in-vivo pain castastrophizing induction.
What is being measured
The primary outcome is the main question the study is designed to answer.
Interleukin-6
Measured: cross-sectional
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2008 (estimated)
- Study startFeb 2007
- Primary completionDec 2007
- Study completionDec 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic PainStudies of the same condition, open and under way.
- More trials run by Oregon Health and Science UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Single group
- Enrolment
- 47 participants (actual)
Sponsor and investigators
- Lead sponsor
- Oregon Health and Science University
- Sponsor type
- University, hospital or other
- Collaborators
- American Pain Society
- Responsible party
- Principal investigator, Beth Darnall, PhD, Oregon Health and Science University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00677911
- Sponsor's protocol ID
- OCTRI975
- Status last verified
- Jul 2019
- First submitted
- 13 May 2008
- Last updated
- 26 Jul 2019
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 26 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Immunologic Response to Negative Cognition in Persons With Chronic Pain
- ClinicalTrials.gov ID
- NCT00677911
- Acronym / sponsor ID
- OCTRI975
- Conditions
- Chronic Pain
- Keywords
- Chronic pain, Interleukin-6, pain catastrophizing, cytokines, cortisol
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 47 participants (actual)
- Lead sponsor
- Oregon Health and Science UniversityUniversity, hospital or other
- Collaborators
- American Pain Society
- Study start
- Feb 2007
- Primary completion
- Dec 2007 (actual)
- Study completion
- Dec 2007 (actual)
- First posted
- 15 May 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Principal Investigator/Program Director (Last, First, Middle): Darnall, Beth APS Future Leaders in Pain Small Research Grants Application Page 5 Continuation Format Page
Summary: Chronic pain is stressful, both physically and psychologically. Stressful experiences induce autonomic nervous system arousal, which reliably leads to inflammation and immune suppression. Inflammation then exacerbates existing pain and may be a key factor in both the genesis and maintenance of pain. Stress-induced immune effects are detected two hours (2 hrs) post-stressor, suggesting only a few stressful experiences per day may be sufficient to sustain elevated pain levels1. Cognition has emerged as a potential mediating factor in the relationship between pain and stress. Mentally recreating an emotionally stressful event induces de novo physiological stress1. In other words, thinking about an emotionally charged event down-regulates autonomic stress responses and subsequent immune effects. Therefore, exploring cognition as a mediating factor between stress, pain, and inflammation will inform our understanding of pain pathways, as well as improve treatment for pain.
Study Rationale: The acute stress response induces immunosuppression; however, this relationship has been studied in arbitrary models only (shock avoidance, job interview). This study employs the novel approach of examining stress and immune responses to a personally relevant stressor (pain); prior studies used arbitrary models only (shock avoidance, job interview). Pain offers a highly salient and personal context well-suited for investigation of negative cognitive perseveration. Pain is acutely sensitive to exacerbation via inflammation, and thus the relevance of examining immune effects of rumination on future negative expectations ("expecting the worst") is underscored.
Goal: To test the biological consequences of negative expectations, achieved via an active 10-minute negative cognitive perseveration on a personally relevant stressor: future worsening of one's chronic pain condition. Biological stress response will be measured via heart rate (HR), blood pressure (BP) and serum cortisol. Impact of negative cognition on inflammation will be measured using interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) as biomarkers of immune function, controlling for depression and pain catastrophizing. This study aims to inform the understanding of pain mechanisms.
Aim 1: Determine the magnitude of an autonomic stress response to an induction of negative cognition.
Aim 2: Determine immune effects of the experiment-induced stress response.
Aim 3: Establish whether a pre-existing tendency to catastrophize mediates the relationship between experiment-induced negative perseveration and immune effects.
Aim 4: Establish whether stress-related increases in IL-6 remain elevated post 2 hrs.
Detailed description
Methods: This prospective study examines the magnitude of biological stress and subsequent immunologic changes in response to negative cognitive perseveration. Five physiological measurement time points occur over the course of the 3 hour experiment.
Demographics and health characteristics of interest: gender, marital status, smoking status, education level, race, height, weight, body mass index, medical comorbidity, psychological comorbidity, medications (for inflammation, pain, or psychiatric conditions).
Inclusionary Criteria
- >18 years of age; <65 years of age
- Non-inflammatory musculoskeletal patients presenting for evaluation at Oregon Health \& Science University (OHSU) Comprehensive Pain Center (CPC)
Exclusionary Criteria
- Active or recent virus/infection
- Thought disorder, Suicidality,
- Substance Abuse
- Active corticosteroid regimen
- Pregnancy
- Limited venous access
- Former intravenous drug user
Enrollment: All persons presenting for evaluation at the CPC who meet study criteria will be offered the option to participate in the study. Approximately 60 new pain patients are evaluated by psychology monthly and we expect to obtain our goal of 40 participants within 6 months. Informed consent will be obtained in compliance with OHSU Institutional Review Board protocol. Subjects will receive $100 gift certificate compensation, even if they fail to complete the study. We anticipate a low completion failure rate as the study is completed in one 3-hour time block. Study times will be standardized to account for circadian effects. Participants will be told to arrive having eaten a light breakfast with minimal caffeine consumption (e.g., less than 2 cups of coffee). They will be given a subject number and their psychiatric diagnoses will be blinded to prevent bias. The study involves gathering 5 serum samples and thus participants will be catheterized by nursing staff to minimize physiological stress.
Principal Investigator/Program Director (Last, First, Middle): Darnall, Beth APS Future Leaders in Pain Small Research Grants Application Page 7 Continuation Format Page
Study site: The study will be conducted at the NIH-funded General Clinical Research Center (GCRC). The GCRC provides state of the art resources including research space, specialized research nurses to perform blood draws and gather biodata, biostatisticians, and sophisticated laboratories to perform serum biomarker analysis. OHSU's GCRC is Oregon's premier multidisciplinary patient-oriented research facility and is housed in the same building as the CPC, thus minimizing travel burden on participants.
Active Stress Induction: Negative Cognitive Perseveration On their experiment day, participants will interface with a licensed clinical psychologist who did not perform their clinical interview and who is blinded to their diagnoses. The psychologist will instruct the participant talk for 10 minutes about the worst aspects of their pain, to discuss their loss of control over their situation, the negative impact pain has had on their life and others. They will be guided to imagine that their situation will progressively worsen, and to focus on how badly they will feel as a result. Two measures of induction efficacy will be given: subjective verbal rating (0-10) and objective rating by attending psychologist (0-10). The intervention ends at 10 minutes and the remainder of the study involves biodata measurement.
Study ends at 2.5 hrs post induction following the final blood draw. The psychologist will debrief subjects and will assess their affective state. Their subjective units of distress will be checked. Persons who are in a continued negative cognitive state will receive 30 minutes of Cognitive Behavioral Therapy (CBT) by the on-site psychologist. Care will be taken not to allow participants to leave the study site in distress. Participants will receive follow up psychology care at the CPC as indicated in their treatment plan.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Single group
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- ages 18-65
- chronic musculoskeletal pain
- being treated for chronic pain at OHSU
Key exclusion criteria (7 listed)
- suicidality or thought disorder
- pregnant
- poor venous access
- current corticosterioid regimen
- recent or active virus or infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| In-vivo pain catastrophizing inductionAll participants underwent a 10-minute in-vivo pain castastrophizing induction. | Behavioural | – |
Primary outcome
Interleukin-6
Time frame: cross-sectional
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jul 2019.
Related trials for Chronic Pain
Recruiting
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Effect of Lumbar Stabilization Exercises With and Without YTWL (Scapular Stabilization Exercises) on Reducing Chronic Low Back Pain and Related Disability. A Randomized Clinical Trial,
Chronic Non Specific Mechanical Low Back Pain
Not yet recruiting
Comparing Non-Medicine Strategies for Improving Low Back Pain
Chronic Low-back Pain (cLBP), High-Impact Chronic Pain (HICP)
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing In-vivo pain catastrophizing induction in people with Chronic Pain, run by Oregon Health and Science University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Interleukin-6 (time frame: cross-sectional). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jul 2019.